BERLIN--(BUSINESS WIRE)--JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of BioNTech AG (Mainz, Germany), and the Cancer Immunotherapy Trials Network (CITN, Seattle, WA, USA) today agreed on the use of JPT’s PepMixTM Peptide Pool Platform to support CITN’s clinical cancer trials and cancer research related efforts.
